Key information

🔎 Fund Overview

MeiraGTx Holdings PLC is an integrated, clinical stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. It has six programs in clinical development and a pipeline of preclinical and research programs. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-Linked Retinitis Pigmentosa Associated with Mutations in the RPGR Gene; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the Treatment of LCA4. It also provides AAV-hAQP1 for the Treatment of Radiation-Induced Grade 2/3 Xerostomia, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy and others.